Clinical trial
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
NCT00003370 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003370 |
|---|---|
| Title | Irofulven in Treating Children With Recurrent or Refractory Solid Tumors |
| Official title | A Trial of MGI 114 in Children With Solid Tumors: A Pediatric Oncology Group Phase I Cooperative Agreement Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | irofulven |
| Enrollment | 12 |
| Start date | Aug 1, 1998 |
| Primary completion | Mar 1, 2006 |
| First posted | Feb 9, 2004 |
| Last update posted | Feb 5, 2013 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: